echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > China NMPA accepts application for clinical trial of PD-1/TGF-β bifunctional fusion protein

    China NMPA accepts application for clinical trial of PD-1/TGF-β bifunctional fusion protein

    • Last Update: 2021-03-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, the Shanghai real-Jun Biotechnology Co.


    management

    JS201 is a bi-functional fusion protein developed by Junshi Biotech using its proprietary technology, which can simultaneously target PD-1 and TGF-β (transforming growth factor-β).


    JS201 is the first product that targets PD-1/TGF-β to be approved for clinical trials in China.


    Junshi Biosciences is the first Chinese pharmaceutical company in China to obtain an anti-PD-1 monoclonal antibody sales license.


    FDA

    Currently, Junshi Biosciences has more than 2,000 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing and Guangzhou).


     

    Original source:

    Original source:

    https://target="_blank" rel="noopener">https:// style="vertical-align: inherit;"> https:// leave a message here

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.